Smallpox projects send stocks soaring

The discovery of monkeypox in several countries has led to share price increases at a number of companies with smallpox vaccines or treatments in their portfolios, including Bavarian Nordic.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Reports of monkeypox in several European countries have sent Bavarian Nordic’s share price soaring. On Thursday May 19, it had jumped by 30%, and by Friday lunchtime, this had increased by a further 19%.

The outbreak of the rare disease has sparked huge international attention, coming hot on the heels of the Covid-19 pandemic, and Bavarian Nordic is currently the only firm in the world with an approved vaccine for the illness. However, other companies with smallpox vaccines or treatment options in their portfolios are also being rewarded by the equity markets, Dow Jones Newswire reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs